Sign In
Buy ITCI
$131.87
+0 (+0%)
At Close: Jul 01, 2025
Intra-Cellular Therapies to Host Second Quarter 2022 Financial Results Conference Call and Webcast
08:00am, Tuesday, 02'nd Aug 2022
NEW YORK, Aug. 02, 2022 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central ner
Intra-Cellular Therapies (ITCI) Expected to Beat Earnings Estimates: Should You Buy?
02:01pm, Monday, 01'st Aug 2022 Zacks Investment Research
Intra-Cellular (ITCI) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Benzinga's Top Ratings Upgrades, Downgrades For July 7, 2022
02:04pm, Thursday, 07'th Jul 2022 Benzinga
Upgrades
For Pacific Premier Bancorp Inc (NASDAQ:PPBI), Raymond James upgraded the previous rating of Outperform to Strong Buy. In the first quarter, Pacific Premier Bancorp showed an EPS of $0.70, co
Has HealthEquity (HQY) Outpaced Other Medical Stocks This Year?
01:40pm, Thursday, 07'th Jul 2022 Zacks Investment Research
Here is how HealthEquity (HQY) and Intra-Cellular Therapies (ITCI) have performed compared to their sector so far this year.
What Stocks To Buy This Week? 4 Biotech Stocks To Know
11:19am, Sunday, 15'th May 2022
Should investors pay more attention to these biotech stocks?
Why Intra-Cellular Therapies Stock Rose 21.4% This Week
09:34pm, Thursday, 12'th May 2022 The Motley Fool
Strong sales for the company's only marketed therapy piqued investors' interest.
Why Intra-Cellular Therapies Stock Rose 21.4% This Week
05:34pm, Thursday, 12'th May 2022
Strong sales for the company's only marketed therapy piqued investors' interest.
Why Intra-Cellular Therapies Trounced the S&P 500 Today
10:24pm, Tuesday, 10'th May 2022 The Motley Fool
The biotech notches an extremely convincing first-quarter earnings beat.
Why Intra-Cellular Therapies Trounced the S&P 500 Today
06:24pm, Tuesday, 10'th May 2022
The biotech notches an extremely convincing first-quarter earnings beat.
Robust Uptake Of Antipsychotic Drug Boosts Intra-Cellular's Q1 Earnings
03:04pm, Tuesday, 10'th May 2022
Intra-Cellular Therapies Inc's (NASDAQ: ITCI) Q1 revenues reached $35.0 million, compared to $15.9 million a year ago, beating the consensus of $33.65 million. Net product revenues of Caplyta were $
Intra-Cellular Therapies, Inc. (ITCI) CEO Sharon Mates on Q1 2022 Results - Earnings Call Transcript
02:54pm, Tuesday, 10'th May 2022
Intra-Cellular Therapies, Inc. (NASDAQ:ITCI ) Q1 2022 Earnings Conference Call May 10, 2022 8:30 AM ET Company Participants Juan Sanchez - Vice President, Corporate Communications and Investor Relatio
The Daily Biotech Pulse: Pfizer Acquires Migraine Drugmaker For $11B, Biogen Files For Second Alzheimer's Drug Approval, Longeveron CEO Leaves
01:23pm, Tuesday, 10'th May 2022 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours:
Stocks In Focus
Pfizer Acquires Biohaven For $11B
Pfizer Inc (NYSE: PFE) will acquire Biohaven Pharmaceutical Hold
Intra-Cellular Therapies (ITCI) Reports Q1 Loss, Tops Revenue Estimates
12:45pm, Tuesday, 10'th May 2022 Zacks Investment Research
Intra-Cellular (ITCI) delivered earnings and revenue surprises of 16.13% and 5.16%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Intra-Cellular Therapies Reports First Quarter 2022 Financial Results and Provides Corporate Update
11:30am, Tuesday, 10'th May 2022 GlobeNewswire Inc.
First quarter 2022 results reflect strong CAPLYTA® (lumateperone) launch in bipolar depression
Intra-Cellular Therapies (ITCI) Reports Q1 Loss, Tops Revenue Estimates
09:47am, Tuesday, 10'th May 2022
Intra-Cellular (ITCI) delivered earnings and revenue surprises of 16.13% and 5.16%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
